Sugi Predict

Sugi Predict / Targets / CD47

CD47

Leukocyte surface antigen CD47 · Q08722 · CD47 on Sugi Atlas →

181 patent compounds predicted against CD47, 126 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL24172455 SCHEMBL24172455 0.69 1/20
SCHEMBL29353777 SCHEMBL29353777 0.69 1/20
SCHEMBL23913045 SCHEMBL23913045 0.65 1/20
SCHEMBL20993012 SCHEMBL20993012 0.62 1/20
SCHEMBL30092992 SCHEMBL30092992 0.59 1/20
SCHEMBL30092995 SCHEMBL30092995 0.59 1/20
SCHEMBL21185976 SCHEMBL21185976 0.59 1/20
SCHEMBL30309224 SCHEMBL30309224 0.58 1/20
SCHEMBL30092985 SCHEMBL30092985 0.58 1/20
SCHEMBL30092909 SCHEMBL30092909 0.58 1/20
SCHEMBL30092947 SCHEMBL30092947 0.57 1/20
SCHEMBL16692892 SCHEMBL16692892 0.57 1/20
SCHEMBL16692898 SCHEMBL16692898 0.57 1/20
SCHEMBL16692899 SCHEMBL16692899 0.57 1/20
SCHEMBL19731206 SCHEMBL19731206 0.57 1/20
SCHEMBL19731216 SCHEMBL19731216 0.57 1/20
SCHEMBL24172454 SCHEMBL24172454 0.57 1/20
SCHEMBL30093110 SCHEMBL30093110 0.57 1/20
SCHEMBL19731215 SCHEMBL19731215 0.56 1/20
SCHEMBL13248737 SCHEMBL13248737 0.55 1/20

Clinical trials — most relevant to CD47 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma PHASE1/PHASE2RECRUITING
SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer. PHASE2NOT_YET_RECRUITING
4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma PHASE1/PHASE2RECRUITING
GD2/PSMA Bi-specific CAR-T Cell Therapy PHASE1/PHASE2RECRUITING
Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer PHASE2WITHDRAWN
DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL PHASE2ACTIVE_NOT_RECRUITING
Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors PHASE2COMPLETED
1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck PHASE2ACTIVE_NOT_RECRUITING
Clinical Trial of the TQB2928 Injection in Patients With Advanced Cancers PHASE1UNKNOWN
A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies PHASE1COMPLETED
A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma PHASE1WITHDRAWN
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone PHASE1ACTIVE_NOT_RECRUITING
Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients PHASE1ACTIVE_NOT_RECRUITING
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma PHASE1RECRUITING
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies PHASE1UNKNOWN
Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors PHASE1UNKNOWN
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma PHASE1RECRUITING
GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma. EARLY_PHASE1NOT_YET_RECRUITING
Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC EARLY_PHASE1UNKNOWN
Effect of Storage Condition on CD47 Expression Level in Platelet Concentrate nanUNKNOWN
Don't Eat me Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity. nanUNKNOWN
Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy nanRECRUITING
Myeloid Derived Suppressor Cells Control by Signal Regulatory Protein-alpha: Investigation in Hepatocellular Carcinoma nanCOMPLETED
Evaluation of CD47, Do Not Eat Me Signal Expression in Chronic Myeloid Leukemia nanNOT_YET_RECRUITING
Characterisation of TLR4+ Blood Cells in Patients With Solid Cancer nanRECRUITING
Study of an Innovative Therapy Using CAR-T Cells Targeting IL-1RAP in Patients With High-Risk Myelodysplastic Syndromes (MDS nanNOT_YET_RECRUITING
Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma? nanRECRUITING
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy nanWITHDRAWN
Thymoglobulin: Presence and Affect in the Central Lymphatic Compartment nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CD47 binder may also engage these)

ProteinNameSimilarity
Q5REL0 — 1.000 Q5REL0 →
Q9GKE8 — 1.000 Q9GKE8 →
Q9N0K1 — 1.000 Q9N0K1 →
P97829 — 0.999 P97829 →
Q61735 — 0.995 Q61735 →
Q5VJ70 — 0.977 Q5VJ70 →
Q62611 — 0.977 Q62611 →
P21995 — 0.976 P21995 →
Q5R804 — 0.975 Q5R804 →
Q59I63 — 0.975 Q59I63 →
Q6PCB8 — 0.975 Q6PCB8 →
P21061 — 0.975 P21061 →
Q9Z2P3 — 0.974 Q9Z2P3 →
Q8K4F0 — 0.974 Q8K4F0 →
Q9D5K1 — 0.974 Q9D5K1 →
B0CLX4 — 0.974 B0CLX4 →
P20352 — 0.974 P20352 →
Q9HBV2 — 0.974 Q9HBV2 →
P0DTU3 — 0.973 P0DTU3 →
Q9ERS7 — 0.973 Q9ERS7 →
Q9NP60 — 0.973 Q9NP60 →
O88775 — 0.973 O88775 →
Q13478 — 0.973 Q13478 →
P13504 — 0.973 P13504 →
Q13296 — 0.973 Q13296 →
Q8C5C9 — 0.973 Q8C5C9 →
P59823 — 0.972 P59823 →
Q6P7N7 — 0.972 Q6P7N7 →
Q7YQL9 — 0.972 Q7YQL9 →
Q86XK7 — 0.972 Q86XK7 →